These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29120234)

  • 1. Immunogenicity and biomarkers: bioanalytical challenges and considerations.
    Gunn GR; Evans C; Yang E
    Bioanalysis; 2017 Nov; 9(22):1729-1732. PubMed ID: 29120234
    [No Abstract]   [Full Text] [Related]  

  • 2. Analytical considerations for quantitative LC-MS strategies for measuring antibody drug-target engagement in tissues.
    Shipkova P; Ciccimaro E; Olah TV
    Bioanalysis; 2017 Dec; 9(23):1845-1847. PubMed ID: 29171760
    [No Abstract]   [Full Text] [Related]  

  • 3. Biomarker measurements: how far have we come and where are we heading?
    Amaravadi L
    Bioanalysis; 2016 Dec; 8(23):2383-2386. PubMed ID: 27855506
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of matrix-associated soluble factors on the specificity of the immunogenicity assessment.
    Bautista AC; Wullner D; Moxness M; Swanson SJ; Chirmule N; Jawa V
    Bioanalysis; 2010 Apr; 2(4):721-31. PubMed ID: 21083270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parallelism experiments in biomarker ligand-binding assays to assess immunological similarity.
    King LE
    Bioanalysis; 2016 Dec; 8(23):2387-2391. PubMed ID: 27855507
    [No Abstract]   [Full Text] [Related]  

  • 6. Unwanted immunogenicity: lessons learned and future challenges.
    Wadhwa M; Thorpe R
    Bioanalysis; 2010 Jun; 2(6):1073-84. PubMed ID: 21083209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates.
    Stephan JP; Kozak KR; Wong WL
    Bioanalysis; 2011 Mar; 3(6):677-700. PubMed ID: 21417735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioanalytical method development: considering information from a suite of complementary methods.
    Fountain ME
    Bioanalysis; 2012 Jan; 4(2):115-9. PubMed ID: 22250793
    [No Abstract]   [Full Text] [Related]  

  • 9. Assessing specificity for immunogenicity assays.
    Swanson SJ; Chirmule N
    Bioanalysis; 2009 Jun; 1(3):611-7. PubMed ID: 21083156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity: prediction, detection and effective assay development.
    Gorovits B
    Bioanalysis; 2010 Sep; 2(9):1539-45. PubMed ID: 21083282
    [No Abstract]   [Full Text] [Related]  

  • 11. 16th Annual Land O'Lakes Bioanalytical Conference.
    Burns EC; Guthrie RH; Fluhler EN; Stubbs RJ; Bateman K; King L; Moran J
    Bioanalysis; 2015 Nov; 7(21):2731-4. PubMed ID: 26563751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical ligand binding reagent preparation/selection: when specificity depends on reagents.
    Rup B; O'Hara D
    AAPS J; 2007 May; 9(2):E148-55. PubMed ID: 17614357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond classical derivatization: analyte 'derivatives' in the bioanalysis of endogenous and exogenous compounds.
    Barnaby OS; Benitex Y; Cantone JL; McNaney CA; Olah TV; Drexler DM
    Bioanalysis; 2015 Oct; 7(19):2501-13. PubMed ID: 26466806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays.
    Zoghbi J; Xu Y; Grabert R; Theobald V; Richards S
    J Immunol Methods; 2015 Nov; 426():62-9. PubMed ID: 26255760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory considerations for development of bioanalytical assays for biotechnology products.
    Swann PG; Shapiro MA
    Bioanalysis; 2011 Mar; 3(6):597-603. PubMed ID: 21417729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioanalytical method development and validation: Critical concepts and strategies.
    Moein MM; El Beqqali A; Abdel-Rehim M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Feb; 1043():3-11. PubMed ID: 27720355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioanalytical considerations in the comparability assessment of biotherapeutics.
    Lee JW; Wang YM; Moxness M; DeSilva B
    Bioanalysis; 2011 Mar; 3(6):613-22. PubMed ID: 21417731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global bioanalytical support.
    John Lin Z; Zhang T; Pasas-Farmer S; Brooks SD; Moyer M; Connolly R
    Bioanalysis; 2014 May; 6(10):1349-56. PubMed ID: 24958119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers in the pharmaceutical industry.
    Laterza OF; Plump A; Ming JE; Richards S; Burczynski ME; Wagner JA; Patterson SD
    Clin Chem; 2015 Apr; 61(4):579-83. PubMed ID: 25376580
    [No Abstract]   [Full Text] [Related]  

  • 20. Historical perspective on the development and evolution of bioanalytical guidance and technology.
    Shah VP; Bansal S
    Bioanalysis; 2011 Apr; 3(8):823-7. PubMed ID: 21510754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.